Reliability of blood eosinophil count in steady-state bronchiectasis
Por:
Martínez-García, MA, Olveira, C, Girón, R, García-Clemente, M, Máiz, L, Sibila, O, Golpe, R, Rodríguez-Hermosa, JL, Barreiro, E, Méndez, R, Prados, C, Rodríguez-López, Oscullo, G, de la Rosa, D
Publicada:
1 dic 2025
Resumen:
Rationale: The baseline value of eosinophils in peripheral blood (BEC) has been associated with different degrees of severity, prognosis and response to treatment in patients with bronchiectasis. It is not known, however, if this basal value remains constant over time. Objectives: The aim of this study was to assess whether the BEC remains stable in the long term in patients with bronchiectasis. Methods and measurements Patients from the RIBRON registry of bronchiectasis diagnosed by computed tomography with at least 2 BEC measurements one year apart were included in the study. Patients with asthma and those taking anti-eosinophilic drugs were excluded. Reliability was assessed using the intra-class correlation coefficient (ICC). A patient with a BEC of at least 300 cells/uL or less than 100 cells/uL was considered eosinophilic or eosinopenic, respectively. Group changes over time were also calculated. Main results: Seven hundred and thirteen patients were finally included, with a mean age of 66.5 (13.2) years (65.8 % women). A total of 2701 BEC measurements were performed, with a median number of measurements per patient of 4 (IQR: 2-5) separated by a median of 12.1 (IQR: 10.5-14.3) months between two consecutive measurements. The ICC was good (>0.75) when calculated between two consecutive measurements (approximately one year apart) but had dropped significantly by the time of the next annual measurements. Similarly, the change from an eosinophilic or eosinopenic patient to a non-eosinophilic or non-eosinopenic patient, respectively, was less than 30 % during the first year with respect to the baseline value but was close to 50 % in later measurements. Conclusions: Given the significant changes observed in the baseline value of the BEC over time, its monitoring is necessary in patients with bronchiectasis in order to more reliably assess its usefulness.
Filiaciones:
Martínez-García, MA:
Hosp Univ & Politecn La Fe, Serv Neumol, Valencia, Spain
ISCIII, CIBERES Enfermedades Resp, Madrid, Spain
Olveira, C:
Univ Malaga, Hosp Reg Univ Malaga, Serv Neumol, Inst Invest Biomed Malaga IBIMA, Malaga, Spain
Girón, R:
Hosp Univ Princesa, Serv Neumol, Inst Invest Sanit, Madrid, Spain
García-Clemente, M:
Hosp Univ Cent Asturias, Serv Neumol, Oviedo, Asturias, Spain
Máiz, L:
Hosp Ramon & Cajal, Serv Neumol, Madrid, Spain
Sibila, O:
Hosp Clin Barcelona, Serv Neumol, Barcelona, Spain
Golpe, R:
Hosp Lucus Augusti, Serv Neumol, Lugo, Spain
Rodríguez-Hermosa, JL:
Hosp San Carlos, Serv Neumol, Madrid, Spain
Barreiro, E:
ISCIII, CIBERES Enfermedades Resp, Madrid, Spain
Hosp Mar IMIM, Serv Neumol, CIBERES, UPF, Barcelona, Spain
Méndez, R:
Hosp Univ & Politecn La Fe, Serv Neumol, Valencia, Spain
ISCIII, CIBERES Enfermedades Resp, Madrid, Spain
Prados, C:
Hosp La Paz, Serv Neumol, Madrid, Spain
Rodríguez-López:
Hosp San Agustin, Serv Neumol, Aviles, Asturias, Spain
Oscullo, G:
Hosp Univ & Politecn La Fe, Serv Neumol, Valencia, Spain
de la Rosa, D:
Hosp Santa Creu & Sant Pau, Serv Neumol, Barcelona, Spain
Green Submitted, gold
|